The objectives of this study are (i) to evaluate the efficacy of oral immunotherapy to pistachio by evaluating the daily oral tolerance of 2g pistachio, by evaluating the long-term tolerance of 15g pistachio (sustained unresponsiveness) and by decreasing pistachio-specific IgE, (ii) evaluating the efficacy of pistachio immunotherapy on cashew tolerance, (iii) and to evaluate the safety of pistachio immunotherapy.
Study Type
OBSERVATIONAL
Enrollment
50
Oral immunotherapy to pistachio
Centre Hospitalo-Universitaire de Nancy
Vandœuvre-lès-Nancy, France
Absence of moderate to severe allergic reactions
with daily intake of 2g of pistachio
Time frame: during the 6 months of maintenance
Frequency and severity of allergic reactions
Time frame: during the dose escalation phase and during the maintenance phase (first 6 months, 1st year, 2nd year, 3rd year)
Decrease in specific IgE and increase of IGg4 to pistachio
Time frame: during the dose escalation phase and during the maintenance phase (first 6 months, 1st year, 2nd year, 3rd year)
Tolerance of 1, 2, 4, 8g in isolated doses and 15 g in total cumulative dose of pistachio
during an oral pistachio challenge test
Time frame: 3 months after stopping daily consumption of 2g pistachio
Tolerance of 1, 2, 4, 8g in isolated doses and 15 g in total cumulative dose of cashew nut
during an oral cashew nut challenge test
Time frame: 3 months after stopping daily consumption of 2g pistachio
Reactogenic or tolerogenic threshold of cashew nuts
Time frame: during the dose escalation phase and during the maintenance phase (first 6 months, 1st year, 2nd year, 3rd year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.